Abstract
Introduction
Pectins have anti‐inflammatory properties on intestinal immunity through direct interactions on Toll‐like receptors (TLRs) in the small intestine or via stimulating microbiota‐dependent effects in the large intestine. Both the degree of methyl‐esterification (DM) and the distribution of methyl‐esters (degree of blockiness; DB) of pectins contribute to this influence on immunity, but whether and how the DB impacts immunity through microbiota‐dependent effects in the large intestine is unknown. Therefore, this study tests pectins that structurally differ in DB in a mouse model with Citrobacter rodentium induced colitis and studies the impact on the intestinal microbiota composition and associated attenuation of inflammation.
Methods and Results
Both low and high DB pectins induce a more rich and diverse microbiota composition. These pectins also lower the bacterial load of C. rodentium in cecal digesta. Through these effects, both low and high DB pectins attenuate C. rodentium induced colitis resulting in reduced intestinal damage, reduced numbers of Th1‐cells, which are increased in case of C. rodentium induced colitis, and reduced levels of GATA3+ Tregs, which are related to tissue inflammation.
Conclusion
Pectins prevent C. rodentium induced colonic inflammation by lowering the C. rodentium load in the caecum independently of the DB.
Keywords: Citrobacter rodentium, colitis, degree of blockiness, degree of methyl‐esterification, microbiota, pectin
Pectins with a low or a high degree of blockiness (DB) both increase microbial diversity and low C. rodentium load in cecal digesta. The pectins protected independent of the DB from C. rodentium‐induced barrier disruption, intestinal damage and inflammation.
1. Introduction
Dietary fibers influence health through immune‐modulating effects,[ 1 , 2 , 3 , 4 , 5 , 6 ] but the exact mechanism explaining the impact of dietary fibers on immunity is not fully understood. It is believed that dietary fibers impact intestinal immunity through direct interaction with immune cells, or indirectly through changing the composition or function of gut microbiota.[ 7 ] Dietary fibers can stimulate intestinal immunity through stimulating the growth of commensals and expose the intestinal immune system to microbial‐derived molecules with immune‐modulating effects, such as lipoteichoic acid, exopolysaccharides, or short‐chain fatty acids (SCFA).[ 8 , 9 ] Additionally, dietary fibers can also preserve intestinal integrity by preventing pathogenic infection and damage by enhancing the growth of commensal communities that compete with pathogens, by having anti‐microbial effects or through decoy effects.[ 10 , 11 ] Microbiota‐dependent effects occur mainly in the large intestine since this intestinal region contains a high abundance of microbiota and a thick mucus layer that prevents direct interactions with intestinal immunity. However, direct effects of dietary fibers occur more at small‐intestinal sites, as it contains a loose mucus layer and a low abundance of the intestinal microbiota.[ 7 ]
Pectin is a dietary fiber with a known impact on intestinal immunity, but this impact of pectin is strongly dependent on its chemical characteristics.[ 12 , 13 , 14 ] Commercial pectins mainly consist of homogalacturonan regions (>70%) that is composed of α‐1‐4 galacturonic acids (GalA) molecules, which form the galacturonic acid backbone. Commercial pectins may also contain other regions in lower abundance, such as Rhamnogalacturonan I and Rhamnogalacturonan II.[ 15 ] The GalA molecules in the homogalacturonan regions can be methyl‐esterified as expressed by the degree of methyl‐esterification (DM).[ 16 ] Methyl‐esters present within the GalA backbone can also be differently distributed which is indicated by the degree of blockiness (DB). Pectins with a high DB have a more blockwise distribution of non‐esterified GalA residues, whereas pectins with a low DB have a more random distribution of non‐esterified GalA residues.[ 17 ] The DM and DB of pectins were essential in the direct effects on TLR2‐1 as the anti‐inflammatory properties of TLR2‐1 were only observed with low DM pectins or intermediate DM (∼DM46) pectins with a higher DB.[ 18 ] The DM and DB were essential in anti‐inflammatory effects of pectins on TLR2‐mediated inflammatory responses in vitro and in mice.[ 14 , 18 ] Additionally, the DM also played an important role in the stimulation of intestinal microbiota communities in several in vitro and in vivo models.[ 19 , 20 , 21 ] How the DB of pectins impacts the microbiota‐dependent modulation of intestinal immunity is unknown.
A way to investigate how stimulation of microbiota composition impacts intestinal immunity is by applying an enteric infection of Citrobacter rodentium in mice.[ 22 ] C. rodentium is the murine equivalent of the human Enteropathogenic Escherichia coli (EPEC) and Enterohemorrhagic Escherichia coli (EHEC), because they share the same virulence mechanism.[ 22 ] These three enteric pathogens can attach to the intestinal epithelium, which leads to the formation of attaching and effacing (A/E) lesions[ 22 ] and the development of colitis that is characterized by crypt elongation, goblet cell depletion, cytokine responses from innate immune cells, and the induction of T cell responses.[ 22 ] This colitis is accompanied by large alterations of the intestinal microbiota composition in mice that is characterized by an overgrowth of the C. rodentium.[ 23 ] Stimulation of the intestinal microbiota with prebiotics or probiotics have been shown to reduce this C. rodentium induced microbiota alterations and reduces the development of colitis.[ 10 , 24 , 25 ]
Since pectins are known to stimulate alterations in intestinal microbiota composition,[ 20 , 21 ] we investigated whether pectins that structurally differ in the DB prevent the development of C. rodentium induced colitis through stimulation of the intestinal microbiota composition. Two high DM pectins (∼DM60) that differed in DB were tested. Mice were fed for 7 days with pectins prior to C. rodentium inoculation. On day 7 of C. rodentium infection, mice were sacrificed and intestinal histology, barrier function, and inflammation were investigated. The impact of pectins on the intestinal microbiota communities and SCFA production was also determined.
2. Experimental Section
2.1. Pectins
Two commercially extracted pectins from orange peel were used in the current study (Andre Pectin Co. Ltd., Yantai, China). Molecular weight, sugar composition, degree of methyl‐esterification (DM), and degree of blockiness (DB) of these pectins were determined as previously described.[ 18 ] Two high DM pectins were used to study the impact of DB as the difference in distribution of non‐esterified GalA residues is larger at this DM compared to low DM. Low DM pectins generally possess a high number blockwise distributed non‐esterified GalA residues (high DB) due to the low level of methyl‐esterified GalA.[ 17 ] Therefore, pectins with a low DM that have different DB do structurally not differ much from each other.
2.2. Mice
C57BL6 female mice (10 weeks old) were obtained from Janvier Laboratories (Le Genest‐Saint‐Isle, France). The experimental use of animals was approved by Animal Ethical Committee of the University of Groningen (CCD application number AVD1050020171487). All mice were acclimatized for 1.5 weeks prior to the start of the experiment. Mice were co‐housed in individual ventilated cages and cohoused with a total number of five mice from similar experimental groups. Control groups were fed ad libitum with RHB‐B diet (AB Diets, Woerden, The Netherlands). Pectin treated mice were fed ad libitum with RHB‐B chow, containing 5% (w/w, human equivalent dose of 8.3 g kg−1) of one of the pectins. Dosage was chosen based on previous studies.[ 26 , 27 ]
2.3. C. rodentium Infection
Mice were fed for 14 days with normal chow or chow containing pectins. After 7 days, 100 µL of Citrobacter rodentium DBS‐100 (American Type Tissue Culture, Manassas, USA) in LB agar (Sigma Aldrich, Zwijndrecht, The Netherlands) was orally administered in a dose of 109 CFU mL−1 to the mice. Control mice received oral administration of LB agar only. Bodyweight and disease activity score (ranging from 0 to 11) were monitored daily after C. rodentium administration as previously described.[ 28 ] At day 14, FITC dextran (4kDa, TdB Consultancy AB, Uppsala, Sweden) was orally administered [600 mg kg−1 in PBS (Lonza, Basel, Switzerland)] to measure large intestinal barrier functioning.[ 29 ] After 4 h, mice were anesthetized with isoflurane/O2 and blood was collected in 50 µL EDTA after heart punction. Mice were terminated by cervical dislocation. Blood was centrifuged at 12 000 x g and plasma was stored at ‐80°C until further analysis. Colon tissues were collected for histological analysis and mesenteric lymph nodes (MLN) were collected to measure T cell frequencies. Cecal tissues were collected to measure tissue cytokines. Cecal digesta was snap frozen in liquid nitrogen and stored at ‐80 °C until microbiota and SCFA analysis.
2.4. Intestinal Barrier Function
FITC‐dextran was measured from plasma to determine the paracellular transport of FITC‐dextran over the intestinal barrier. Plasma was diluted in an equal volume of PBS. Standards (50‐0.156 µg mL−1) were also diluted in PBS. Samples and standards were transferred to a black 96‐wells plate (Costar, Corning incorporate, USA) in a volume of 100 µL. PBS only was used as blank. FITC‐dextran analysis was performed with a microplate spectrophotometer (Clariostar, De Meern, The Netherlands) at an excitation wavelength of 485 nm and an emission wavelength of 528 nm.
2.5. Histology
Colon samples were incubated for 24 h in 4% paraformaldehyde in PBS and embedded in paraffin. Paraffin sections were cut at 4 µM and H&E staining was performed on the slices. The stained slides were scanned at a magnification of 40x using a Hamamatsu slide scanner (Hamamatsu Photonics, Hamamatsu, Japan).
2.6. Cecal Cytokine Measurements
Cecal cytokines were determined as described before.[ 27 ] Briefly, after collection from mice, cecal tissues were washed in PBS. Next, tissues were transferred to 2 mL ice‐cold PBS containing 1x protease inhibitor cocktail (Sigma Aldrich) and homogenized using cell homogenizer for 2 min (Tamson, Zoetermeer, The Netherlands). After this, the cell suspension was centrifuged at 12 000 x g and the supernatant was collected for protein determination and cytokine measurements. Protein determination was quantified using BCA protein assay kit (Thermo Scientific, Etten‐Leur, The Netherlands). TNF‐α, IL‐6, and IL‐10 levels from cecal cell lysates were determined with ELISA (R&D systems, Minneapolis, USA) according to manufacturer's instructions. Cytokine levels were corrected for the protein levels in the cell lysates.
2.7. T Cell Staining and Flow Cytometry
Cells from MLN were isolated as previously described.[ 30 ] To stain T cells, 1 × 106 MLN cells were transferred to a 96 wells plate and centrifuged for 5 min. The cells were washed once with PBS and incubated for 15 min with ZombieNIR (Table 1 ). After this step, the cells were washed with FACS buffer (PBS + 2% dFCS) and incubated for 10 min with extracellular blocking buffer containing 20% (v/v) rat serum (Jackson, Newmarket, UK), 78% (v/v) FACS buffer and 2% (v/v) FC block (eBioscience, Vienna, Austria). Next, cells were incubated with 25 µL extracellular antibody mix (Table 1) for 30 min. Then the cells were washed with FACS buffer and incubated for 30 min with FACS lysing buffer (BD Biosciences, Breda, the Netherlands) containing 2% PFA to fixate the cells. Next, the cells were washed twice with permeabilization buffer consisting of demi water + 5% (v/v) PERM (Invivogen, Toulouse, France). Then the cells were intracellularly blocked for 10 min with intracellular blocking buffer (20% (v/v)) normal rat serum in permeabilization buffer. After this step, cells were incubated for 30 min with 50 µL intracellular antibody mix (Table 1). This was followed by two washing steps with permeabilization buffer. Finally, the cells were resuspended in 100 µL FACS buffer and stored at 4°C until analysis within 16 h. In all centrifugation steps, cells were centrifuged at 600 x g for 3 min at 4°C. Incubation steps were performed on ice. FMO controls were used to set the gates (Supplementary Figure S1, Supporting Information).
Table 1.
Marker | Fluorchrome | Antibody mix | Dilution | Company (catalogue number) |
---|---|---|---|---|
CD3 | BV605 | Extracellular | 25x | Biolegend (100 237) |
CD4 | CD4‐PE‐Cy7 | Extracellular | 100x | Biolegend (100 422) |
CD8 | CD8‐ PerCP‐Cy5.5 | Extracellular | 50x | Biolegend (100 734) |
Tbet | BV421 | Intracellular | 10x | Biolegend (644 816) |
GATA3 | AF647 | Intracellular | 100x | BD (560 068) |
Rorγt | PE | Intracellular | 100x | eBioscience (12‐6981‐80) |
Foxp3 | FITC | Intracellular | 50x | eBioscience (11‐5773‐82) |
dead/live | Zombie NIR | ‐ | 1000x | Biolegend (423 105) |
The FACSverse flow cytometer system was used to measure the samples (BD Biosciences Franklin Lakes, USA), using the FACSsuite software. Analysis was performed by FCS Express software version 6 (De Novo Software, Pasadena, USA).
2.8. DNA Extraction Cecal Digesta for Microbiota Analysis
Cecal digesta was collected and immediately snap‐frozen in screw caps in liquid nitrogen and stored −80°C until DNA isolation. For DNA isolation approximately 0.25 g of digesta was collected and DNA was isolated using QIAmp Powerfecal DNA kit (QIAGEN, Hilden, Germany). DNA concentration was measured with NanoDrop ND‐1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). Digesta mass was weighted before each isolation step.
2.9. 16S rRNA Gene Sequencing, Quality Control, and Taxonomy Assignment
Samples were sent to NOVOGENE (Cambridge, UK) for sequencing, quality control, and taxonomy assignment. In short, DNA was used for the amplification of the V3‐V4 region of bacterial 16S rRNA using 341F primer (5’‐CCTAYGGGRBGCASCAG‐3’) and 806R primer (5’‐GGACTACNNGGGTATCTAAT‐3’) containing a six‐nucleotide barcode (Novogenes, Cambridge, UK). The PCR product was then selected for proper size and purified for library preparation. The same amount of PCR product from each sample was pooled, end polished, A‐tailed, and ligated with adapters. After purification, the library was analyzed for size distribution, quantified using real‐time PCR, and sequenced on NovaSeq 6000 SP flowcell with PE250.
Sequences analysis was performed by Uparse software (Uparse v7.0.1001 http://drive5.com/uparse/) using all the effective tags. Sequences with ≥97% similarity were assigned to the same operational taxonomic units (OTUs). Representative sequence for each OTU was screened for further annotation. For each representative sequence, Mothur software was performed against the SSUrRNA database of SILVA Database (http://www.arb‐silva.de/) for species annotation at each taxonomic rank (Threshold: 0.8∼1) (kingdom, phylum, class, order, family, genus, species). Alpha diversity, including shannon index and Chao1 index, or Beta diversity on both weighted and unweighted unifrac were calculated with QIIME (Version 1.7.0) and displayed with Graphpad software (Version 8.4.1).
2.10. Real‐time PCR on Cecal Digesta to Determine C. rodentium Load
To measure C. rodentium load in the caecal digesta, real‐time PCR was performed on DNA that was isolated from the cecal digesta. DNA was also isolated from C. rodentium cultures using QIAmp Powerfecal DNA kit (QIAGEN) to make a standard of 0 – 2.1×1010 CFU. Forward primer 5’‐ATGCCGCAGATGAGACAGTTG‐3’ and reverse primer 5’‐ GTCAGCAGCCTTTTCAGCTA‐3’ were previously designed and specific for EspB gene of C. rodentium.[ 31 ] Next, isolated DNA from standards and 12.5 ng cecal DNA was mixed with 10 mM primers and with SYBRgreen mastermix (Roche, Basel, Switzerland). The reaction was started with an enzyme activation step of 10 min at 95°C. Then, the amplification reaction was performed for 40 cycles, starting with denaturation for 15 s at 95°C, followed by annealing for 60 s at 60°C, and extension for 30 s at 72°C in a ViiA Real‐time PCR System (Applied Biosystems, Foster City, CA, USA). C. rodentium load in CFU was calculated from CT values of the standard curve and corrected to CFU/gram by using digesta mass that was measured for DNA isolation.
2.11. SCFA Profiling
For SCFA analysis, 20–150 mg caecum content was diluted in 150 µL ultrapure water, mixed, and centrifuged at 20 000 x g for 10 min. Next, 100 µL supernatant was used for SCFA analysis using a Dionex Ultimate 3000 HPLC (Thermo Scientific, Dionex, Sunnyvale, CA, USA). Then, 10 µL sample was injected to an ion‐exclusion Aminex HPX‐87H column (7.8×300 mm) combined with a guard column (Bio‐Rad, Hercules CA, USA). The elution was monitored by refractive index detection (Shodex RI 101; Showa Denko K.K., Tokyo, Japan). Elution was done with a flow rate of 0.6 mL min−1 using 5.0 mM H2SO4 at 65°C.[ 32 ] Standard solutions of lactic acid, succinic acid, acetic acid, propionic acid, butyric acid, isovaleric acid, and isobutyric acid were prepared in concentrations of 0.03125–2 mg mL−1. Data were processed using Chromeleon 7.2 (Thermo Scientific, Dionex, Sunnyvale, CA, USA). SCFA concentrations were expressed µmol mg−1 dry matter to correct for the potential impact of digest consistency. Dry matter content was determined by drying the samples in an oven overnight at 60°C.
2.12. Statistics
Past3 software was used for Permanova, and Simper similarity test.[ 33 ] Graphpad software (Version 8.4.1) (La Jolla, CA, USA) was used to measure statistical differences for crypt depth, intestinal barrier function, cecal cytokine production, T cell frequencies, and individual bacterial families and species. Normal distribution was confirmed using the Kolmogorov‐Smirnov test. Statistical differences between control, C. rodentium, C. rodentium + DM59 (low DB) pectin, C. rodentium + DM64 (high DB) pectin were tested with t‐test (comparison two groups) and one‐way ANOVA (comparison multiple groups) for parametrically distributed data and with Mann‐Whitney (comparison two groups) and Kruskal‐Wallis (comparison multiple groups) for non‐parametrically distributed data. Post‐testing was performed with Dunnet to test statistical differences between C. rodentium and pectin treated mice (p < 0.05 was considered as statistically significant; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). p between 0.05 and 0.10 were considered as a trend. p‐values of microbiota data were corrected for multiple testing by the false discovery rate (FDR) of Benjamini–Hochberg (FDR < 0.05).
3. Results
3.1. Structural Characteristics of Pectins
Pectins were characterized for the degree of methyl‐esterification (DM), degree of blockiness (DB), molecular weight, and sugar composition (Table 2 ). The homogalacturonan pectins were rather similar in sugar composition and molecular weight. The pectins also had a similar DM range (59% and 64%), but they did differ in DB. The DM59 pectin had a DB of 17%, whereas the DM64 pectin had a higher DB of 37%. These findings demonstrate that both pectins possess around 40% non‐esterified GalA residues of which 37% are distributed in blocks in the DM64 pectin and 17% of the non‐esterified GalA residues are distributed in blocks in the DM59 pectin.
Table 2.
Pectin | origin | DB [%] | Mw | Sugar composition [mol%] | Carbohydrate content [%] | ||||
---|---|---|---|---|---|---|---|---|---|
Rha | Ara | Gal | Glc | UA | |||||
DM59 | orange | 17 | 86 000 | 1 | 3 | 8 | 1 | 88 | 87 |
DM64 | orange | 37 | 92 000 | 1 | 7 | 8 | 2 | 82 | 81 |
Degree of methyl‐esterification (DM), Degree of blockiness (DB), Weight‐average molecular weight (Mw), and sugar composition of the pectins. Rha, rhamnose; Ara, arabinose; Gal, Galactose; Glc, Glucose; UA, Uronic Acid.
3.2. Both Low DB and High DB Pectins Exert a Protective Effect Against C. rodentium‐Induced Colonic Damage
The impact of supplementation of low DB and high DB pectin structures on C. rodentium‐induced colitis was investigated. Mice received pectins for 14 days and at day 7 after start of pectin supplementation (Figure 1A), C. rodentium was orally administered to mice.
Bodyweight increased in control mice during the experiment (Figure 1B), which was not observed in mice receiving C. rodentium nor in mice receiving C. rodentium + pectins (p < 0.01 from AUC). Disease activity score gradually increased after administration of C. rodentium (Figure 1C). However, mice treated with C. rodentium + DM59 (low DB) pectin or mice treated with C rodentium + DM64 (high DB) pectin showed a lower disease activity score than mice treated with C. rodentium. The disease activity score did not significantly differ from control mice. These results corroborated the findings on bacterial load of C. rodentium in caecal digesta samples (Figure 1D). C. rodentium treated mice had a high load of 4.31×108 CFU/g (p < 0.0001) in caecal digesta, whereas C. rodentium + DM59 (low DB) pectin treated mice had a lower C. rodentium load of 1.68×107 CFU/g (p < 0.05 vs C. rodentium treatment) while C. rodentium + DM64 (high DB) pectin treated mice had a lower C. rodentium load of 2.14×107 CFU/g (p < 0.05 vs C. rodentium treatment). Thus, low and high DB pectin treatments both resulted in a lower disease activity score and lower C. rodentium load.
Next, the protective effect of pectins was investigated on C. rodentium‐induced colonic damage and C. rodentium‐induced intestinal barrier dysfunction. Histological analysis (Figure 2A) of the colon revealed that C. rodentium induced severe intestinal damage that is characterized by goblet cell depletion, epithelial damage, and increased crypt length (Figure 2B). C. rodentium induced a crypt length of 187.3 µm which was higher (p < 0.0001) than in control mice which had a crypt length of 111.4 µm. Pectins protected from this C. rodentium‐induced crypt elongation as C. rodentium + DM59 (low DB) treated mice had a crypt length of 129.3 µm (p < 0.01 compared to C. rodentium) and C. rodentium + DM64 (high DB) pectin treated mice showed a crypt length of 142.7 µm (p < 0.05 compared to C. rodentium). These protective effects were not different between the pectins.
Intestinal barrier function disruption was also beneficially influenced by the pectins (Figure 2C). C. rodentium treated mice had a plasma FITC‐dextran concentration of 776.6 µg/ml which was significantly (p < 0.01) higher than the 362.6 µg/ml of control mice. The C. rodentium + DM59 (low DB) pectin treated mice and C. rodentium + DM64 (high DB) pectin treated mice had a significant lower concentration of plasma FITC‐dextran of respectively 323.4 µg/ml (p < 0.01 vs C. rodentium) and 464.8 µg/ml (p < 0.05 vs C. rodentium). These results suggest together that both low and high DB pectins prevent C. rodentium‐induced colonic damage and attenuate C. rodentium‐induced intestinal barrier dysfunction.
3.3. Pectins Prevent a C. rodentium‐Induced Increase of pro‐Inflammatory T cell Subsets, but they do not Attenuate C. rodentium‐Induced Cytokine Secretion in the Caecum
Since pectins prevent C. rodentium‐induced intestinal damage, we investigated the impact of the different pectins on C. rodentium‐induced immune responses. First, levels of the cytokines IL‐6, TNF‐α, and IL‐10 from cecal tissues were determined. As shown in Figure 3 , C. rodentium induced a significant increase of 66.5% (p < 0.05) of cecal TNF‐α, whereas cecal IL‐6 and IL‐10 were unaffected by the C. rodentium infection. Pectin supplementation did not prevent this increase of TNF‐α as the DM59 (low DB) pectin‐treated mice also had a 69.2% (p < 0.05 compared to control) higher level and the DM64 (high DB) pectin treated mice had a 71.8% (p < 0.01 compared to control) higher level of cecal TNF‐α levels after C. rodentium infection.
The impact of pectins on C. rodentium induced T cell frequencies in the MLN was also investigated. T helper cell subsets were impacted by C. rodentium infection. C. rodentium increased Th1 levels with 54.9% (p < 0.05, Figure 3G), Th2 levels with 50.2% (p < 0.05, Figure 3H), and Th17 levels with 59.8% (p < 0.05, Figure 3I). Regulatory T cell levels were unaffected by C. rodentium treatment (Figure 3J). Both pectins showed a protective effect on these C. rodentium induced T cell frequencies. The DM59 (low DB) and DM64 (high DB) pectins treatments reduced C. rodentium‐induced Th1 levels with 47.2% (p < 0.05) and 50.4% (p < 0.05), respectively. A similar protective effect of both pectins was found on Th2 cells as they reduced C. rodentium‐induced increase in Th2 levels with 49.3% (p < 0.05) and 48.3% (p < 0.05), respectively. However, DM59 (low DB) pectin and DM64 (high DB) pectin treatment did not prevent the increase of Th17 cell frequencies induced by C. rodentium. The pectin treated mice did also not show a difference in Th17 cells compared with control mice, suggesting that the pectins + C. rodentium treatments induce an increase in Th17 cells, but not as high as C. rodentium treated mice. Additionally, the levels of the regulatory T cell subsets Tbet+ Tregs, GATA3+ Tregs, and Rorγt+ Tregs were also measured (Figure 3K‐M). Neither C. rodentium nor C. rodentium + pectin treatments affected Tbet+ Tregs or Rorγt+ Tregs levels, but C. rodentium increased GATA3+ Tregs with 40.7% (p < 0.05). The C. rodentium + DM64 (high DB) pectin treated mice had a 40.8% lower level of GATA3+ Tregs compared to C. rodentium treated mice. The C. rodentium + DM59 (low DB) pectin treated mice had a 24% lower level of GATA3+ Tregs, which is not significantly different from control and C. rodentium treated mice. This suggests that C. rodentium + DM59 (low DB) pectin treatment reduces the C. rodentium‐induced increase in GATA3+ Tregs cells, but not to such a low level as control mice.
3.4. Pectins Did Not Increase the Organic Acid Levels in the Caecum
To investigate whether SCFAs may explain the protective effects of pectins against C. rodentium infection, the levels of the organic acids acetic acid, propionic acid, butyric acid, succinic acid, lactic acid, isobutyric acid, and isovaleric acid were determined in the caecum of the different mice. As shown in Figure 4 , both C. rodentium treatment and C. rodentium + DM59 (low DB) pectin treatment did not change total organic acid levels, whereas C. rodentium + DM64 (high DB) pectin treatment significantly decreased (p < 0.01) total organic levels in caecal digesta (Figure 4A). Most organic acids levels, including the SCFAs butyric acid and acetic acid levels were not changed by C. rodentium treatment or pectin + C. rodentium treatments. Both pectins treatments only showed a lower level of propionic acid and succinic acids compared to control and C. rodentium treatment, respectively (Figure 4C and 4E). These findings suggest that the protective effect against C. rodentium induced damage is not the result of the enhancement of SCFA or organic acid production by the intestinal microbiota.
3.5. Pectins Induce a Different Microbiota Composition Compared to C. rodentium‐Infected and Control Mice
Next, we investigated which specific changes in microbiota composition are induced by the pectins. Differences in microbiota diversity and abundance were determined with 16s RNA sequencing. As shown in Figure 5 , the Shannon index (Figure 5A) and Chao1 index (Figure 5B) revealed that the C. rodentium + DM59 (low DB) pectin treated mice and C. rodentium + DM64 (high DB) pectin treated mice showed higher microbiota diversity (both p < 0.01) and richness (both p < 0.01) compared to C. rodentium‐infected mice in absence of pectin. Additionally, PCoA plots based on unweighted (Figure 5C) and weighted (Figure 5D) UniFrac distances also revealed that treatment with both pectins resulted in a rather similar microbiota composition (Permanova, p > 0.05) differing both from C. rodentium treated mice (Permanova, p < 0.001) and control mice (Permanova, p < 0.001). These findings show that mice treated with both low or high DB pectins had a more diverse and rich microbiota composition than the C. rodentium‐infected mice and the controls.
Next, we investigated which bacterial groups were significantly different in abundance at the family level between the different experimental groups (Figure 5E‐I). Control mice and C. rodentium treated mice showed higher levels of Muribaculaceae (Figure 5F). The levels of Muribaculaceae were 21.0% (p < 0.0001) lower in C. rodentium + DM59 (low DB) pectin treated mice and 26.1% (p < 0.0001) in C. rodentium + DM64 (high DB) pectin treated mice. On the contrary, Lachnospiraceae (Figure 5G) were significantly higher in C. rodentium + pectin treated mice compared to C. rodentium treated mice. Lachnospiraceae was 9.1% (p < 0.05) higher in DM59 (low DB) pectin treated mice and 15.3% higher in DM64 (high DB) pectin‐treated mice (p < 0.001). Specific effects for C. rodentium + DM59 (low DB) pectin‐treated mice were also observed. C. rodentium + DM59 (low DB) pectin‐treated mice had a significant higher level [3.6%, (p < 0.01)] of Ruminococcaceae (Figure 5I) and a significant higher level [4.9%, (p < 0.01)] of Desulfovibrionaceae (Figure 5J) compared to mice treated with C. rodentium only. Typical for the C. rodentium + DM64 (high DB) pectin treatment was a significant higher level (9.4%, (p < 0.01)) of Enterobacteriaceae (Figure 5) compared to C. rodentium only. The level of Bacteroidaceae (Figure 5K) did not differ between the different experimental groups.
To identify which bacterial species explain the variation in microbiota composition between C. rodentium and C. rodentium + pectin treated mice, we performed a SIMPER test (Supplementary Tables 1–S3, Supporting Information). The species contributing most to the variations in microbiota composition and showing significant differences between the experimental groups were plotted in Figure 6 . An increase of specific species from Lachnospiraceae and Bacteroidaceae and a decrease in species from Enterobacteriaceae and Bacteroidaceae contributed to the differences in microbiota composition between mice treated with C. rodentium and the pectins and mice treated with C. rodentium only. E. coli, a species from Enterobacteriaceae, was decreased in all C. rodentium‐treated groups compared to the control. However, various species from Lachnospiraceae, such as Lachnospiraceae bacterium COE1 (Figure 6B), Lachnospiraceae bacterium 615 (Figure 6C), and Clostridium sp. Culture 41 (Figure 6D) were significantly increased in C. rodentium + DM59 (low DB) pectin treated mice (p <0.05; p < 0.05, p < 0.01, respectively) and in C. rodentium + DM64 (high DB) pectin‐treated mice (p <0.05; p < 0.01, p < 0.01, respectively) compared to C. rodentium treated mice. There was also a trend towards an increase in Clostridium sp. Culture 27 (Figure 6E) in these mice. Additionally, compared to C. rodentium treated mice, species from Bacteroidaceae were increased, such as Bacteroides acidifaciens (Figure 6F) in C. rodentium + DM59 (low DB) pectin and C. rodentium + DM64 (high DB) pectin‐treated mice (respectively p <0.05; p < 0.01) and Bacteroides caecimuris (Figure 6E) in C. rodentium + DM64 (high DB) pectin‐treated mice (p <0.05). Another species from Bacteroidaceae, Bacteroides dorei (Figure 6H), was only increased in C. rodentium treated mice and was significant lower in control (p < 0.01) and C. rodentium + DM59 (low DB) pectin (p < 0.0001) and C. rodentium + DM64 (high DB) pectin‐treated mice (p < 0.0001).
4. Discussion
Dietary fibers are known to impact intestinal immunity through microbiota dependent ways.[ 34 ] Pectin is one of these dietary fibers that is known to exert these beneficial effects,[ 7 ] but it is unknown how pectins that structurally differ in the DB influence the microbiota‐dependent impact on intestinal immunity. Therefore, in the current study we explored how high DM pectins that differ in the DB exert anti‐inflammatory properties through modulating intestinal microbiota communities in a model of C. rodentium‐induced colitis. The current study showed that treatment with both tested pectins prevented the development of C. rodentium‐induced colitis in mice. This protective effect was independent of the DB of pectins. Treatment with both pectins reduced intestinal damage, preserved intestinal barrier function, and was associated with a reduced level of specific T cell subsets. These anti‐inflammatory effects of pectins were not derived from the production of SCFAs in the cecum, but may rather be explained by alterations in microbiota composition which reduced the C. rodentium load and there with pathogenicity in the caecum of pectin treated mice.
The lower C. rodentium load in low and high DB pectins treated mice may be responsible for the anti‐inflammatory effect of the pectins on the development of C. rodentium‐induced colitis. A lower C. rodentium exposure to epithelial cells avoids the attachment of C. rodentium to epithelial cells which protects from C. rodentium‐induced epithelial barrier disruption and transmissible murine colonic hyperplasia.[ 11 , 22 , 35 ] In our study we found a reduced crypt length and a reduced barrier disruption in mice treated with both pectins, suggesting that pectins prevent the binding of C. rodentium to epithelial cells and prevent the development of C. rodentium‐induced epithelial damage. Moreover, the lower attachment of C. rodentium to epithelial cells may also be responsible for the limited development of colitis in these mice. Both low and high DB pectins induced anti‐inflammatory effects on C. rodentium‐induced colitis that was characterized by reduced levels of Th1 which are increased in C. rodentium‐induced colitis,[ 22 ] and GATA3+ Tregs which are related to tissue inflammation.[ 36 , 37 ] There was, however, still some level of inflammation in these mice that was characterized by increased levels of TNF‐α and Th17 cells. Together, these findings suggest that pectins lower the C. rodentium load in the digesta which prevents C. rodentium attachment to epithelial cells and the induction of colonic inflammation.
The low and high DB pectins may lower the C. rodentium load in the digesta through several mechanisms. Pectin molecules are known to directly bind with C. rodentium and exert anti‐microbial effects.[ 11 ] The large availability of pectins to interact with C. rodentium through pectin ingestion may inhibit the growth of the pathogen in the caecum. The digestion of the pectins by the intestinal microbiota may, however, change this inhibitory impact of pectin molecules on C. rodentium growth.[ 11 ] Nevertheless, the digested pectin in the form of galacturonic acid (GalA) monomers may be able to inhibit the growth of C. rodentium, because GalA are known to influence the virulence of C. rodentium in the caecum and thereby reduce the overgrowth of the pathogen.[ 38 ] Jimenez et al. [ 38 ] demonstrated that the digestion of pectins leads to the release of GalA, which are sensed by the transcription factor ExuR in C. rodentium.[ 38 ] In absence of GalA, the ExuR transcription factor will stimulate the expression of the virulence genes of C. rodentium which leads to epithelial attachment and colitis. In presence of GalA, however, GalA binds to ExuR and suppresses the expression of specific virulence genes of C. rodentium.[ 38 ] The loss of virulence factors prevents binding of C. rodentium to epithelium and localizes C. rodentium in the luminal digesta. Here, the growth of the pathogen can be outcompeted by other commensal bacteria, which leads to a lower C. rodentium load.[ 39 , 40 ] Overall, the pectin treatment may induce anti‐microbial effects on C. rodentium or prevent the expression of virulence factors by C. rodentium. Consequently, the growth of C. rodentium is outcompeted in the lumen by other commensal bacteria which reduces the C. rodentium load and prevents the development of C. rodentium‐induced colitis.
Our data showed that treatment with the low or high DB pectins induces alterations in microbiota compositions which may prevent C. rodentium pathogenicity and associated colitis. Pectin is known to stimulate Lachnospiraceae communities[ 20 , 21 ] as species from Lachnospiraceae possess pectin‐degrading enzymes.[ 41 ] The increased abundance of Lachnospiraceae by the pectins may enhance the digestion of pectins. This leads to an enhanced galacturonic acid availability for C. rodentium which reduces the virulence of the pathogen and attenuates colitis.
Intestinal SCFAs are important in the regulation of immune function and intestinal homeostasis and have strong anti‐inflammatory properties on C. rodentium‐induce colitis.[ 42 ] It is however challenging to measure SCFA accurately in the intestinal tissues due to the rapid metabolization by intestinal microbiota or intestinal tissues.[ 43 ] Our data demonstrated that despite both pectins induce an increase in SCFA producing bacteria, C. rodentium infected mice treated with DM64 (high DB) showed lower caecal SCFA levels compared to control mice, whereas mice treated with DM59 (low DB) did not experience a lowering of SCFA. This difference in SCFA levels might be explained by a difference in fermentability between the two pectins. A previous study found that readily fermented resistant starches reduced SCFA levels at the peak infection period in C. rodentium infected rats, whereas slowly fermented wheat bran increased SCFA levels.[ 42 ] Pectin degrading enzymes prefer pectin substrates containing large blocks of non‐esterified GalA residues to pectin substrates containing high levels of methyl esters.[ 19 ] DM64 (high DB) pectin may therefore be more readily fermentable than the DM59 (low DB) pectin and may contribute to lower cecal SCFA levels in the DM64 (high DB) treated mice.
C. rodentium infections induce strong immune responses in the colonic tissues that are characterized by increased T cell frequencies and enhanced cytokine levels.[ 22 ] Our data corroborated this finding as we observed enhanced Th17 levels in mice treated with C. rodentium only. Wang et al. demonstrated that this induction of Th17 during C. rodentium infection is strongly supported by Treg cells, because deletion of Treg cells in mice prevented the induction of Th17 cells during C. rodentium infection.[ 44 ] However, our data did not show an enhanced level of Treg cells in C. rodentium infected mice, suggesting that the presence rather than an increase of Treg cells are essential for the induction of Th17 cells. Moreover, the GATA3+ cell frequencies were also increased in mice treated with C. rodentium only, but decreased in mice treated with DM64. GATA3+ Treg cells express ST2 by which they can sense epithelial derived IL‐33, an alarmin which is produced by intestinal epithelial cells upon infection. In response to IL‐33, ST2+ GATA3+ Treg cells get activated and expand.[ 45 ] In the current study the pectins might limit C. rodentium‐induced epithelial damage and prevented thereby the expansion of GATA3+ Treg cells in mice. Furthermore, our data also showed enhanced levels of Th1 and TNF‐α in C. rodentium infected mice, but only Th1 and not TNF‐α levels were reduced by both pectin treatments. Previously it was demonstrated that TNF‐α was not only derived from Th1 cells,[ 46 ] but also from innate immune cells, such as macrophages or dendritic cells during C. rodentium infection in mice.[ 47 , 48 ] These findings suggest therefore that pectins may only limit the induction of T cell responses during C. rodentium infection, but pectins do not prevent the induction of innate immune responses by C. rodentium.
In the large intestine, a thick mucus layer and the high abundance of pectin‐degrading enzymes prevent direct interactions of pectin molecules with the intestinal immune system. Here, pectins can influence intestinal immunity only through microbiota‐dependent effects. This is different for the small intestine which contains a loose mucus layer and a low abundance of microbiota that allow pectins to interact directly with the immune system.[ 7 ] Which pectins impact immunity through direct effects or microbiota‐dependent effects is dependent on specific structural characteristics of pectin.[ 7 ] Our data showed that the DB of pectins is not a structural characteristic that changes the microbiota‐dependent effect of high DM pectins. This in contrast to the DB‐dependent impact of ∼DM46 pectins on small‐intestinal inflammation.[ 14 , 18 ] A DM43 pectins with a high DB induces similar strong inhibiting properties on TLR2‐1 as low DM pectins, whereas a DM49 pectin with a low DB did not inhibit TLR2‐1 strongly.[ 18 ] Small intestinal inflammation was prevented through direct effects of these pectin structures on TLR2‐1 and not through microbiota dependent effects.[ 14 ] The microbiota‐dependent effects of pectins may rather be influenced by the DM of pectins. In the presence of microbes that contain pectin degrading enzymes, low DM pectins are easily digested by microbial enzymes due to the lack of bound methyl‐esters.[ 19 ] This results in a different alteration of intestinal microbiota composition between low and high DM pectins in rats and piglets.[ 20 , 21 ]
Collectively, our study demonstrates that high DM pectins with different DB equally induce anti‐inflammatory properties in mice with C. rodentium infection through microbiota dependent ways. Both tested pectins enhanced the diversity of the intestinal microbiota which may reduce the C. rodentium load in the caecum. Consequently, both pectins prevent the C. rodentium‐induced epithelial damage, intestinal inflammation, and intestinal damage. The pectins may induce antimicrobial effects[ 11 ] on C. rodentium or reduce the virulence of C. rodentium by the interaction of GalA monomers with the transcription factor EspE.[ 38 ] This knowledge on how pectin structures impact immunity through stimulation of the intestinal microbiota can be instrumental in the design of functional food applications. Consumers may profit from high DM pectin consumption as it may stimulate the diversity of the microbiota composition, which can reduce the risk of infection of C. rodentium, EPEC, or EHEC.
Conflict of Interest
The authors declare no conflict of interest.
Author Contributions
M.B., and P.d.V. designed the study. M.B., R.A, and T.K. performed the animal experiments and histology experiments. T cell staining and flow cytometry was performed by A.L assisted by R.A. Both M.B and C.K. isolated DNA for microbiota analysis. Microbiota analysis was performed by M.B. and assisted by M.M.F. E.J. and H.A.S. characterized the pectins and performed SCFA measurements. M.B., and P.d.V. wrote the article. All authors have revised and improved the manuscript.
Supporting information
Acknowledgements
Research of Martin Beukema was performed within the public‐private partnership “CarboKinetics” coordinated by the Carbohydrate Competence Center (CCC, www.cccresearch.nl). CarboKinetics is financed by participating industrial partners Agrifirm Innovation Center B.V., Nutrition Sciences B.V., Cooperatie Avebe U.A., DSM Food Specialties B.V., and VanDrie Holding N.V., and allowances of The Netherlands Organisation for Scientific Research (NWO).
Graphical abstract was created with BioRender.com.
Beukema M., Akkerman R., Jermendi É., Koster T., Laskewitz A., Kong C., Schols H. A., Faas M. M., de P. Vos, Pectins that Structurally Differ in the Distribution of Methyl‐Esters Attenuate Citrobacter rodentium‐Induced Colitis. Mol. Nutr. Food Res. 2021, 65, 2100346. 10.1002/mnfr.202100346
Data Availability Statement
Research data are not shared.
References
- 1. Sonnenburg E. D., Sonnenburg J. L., Cell Metab. 2014, 20, 779. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Maki K. C., Phillips A. K., J. Nutr. 2015, 145, 159S. [DOI] [PubMed] [Google Scholar]
- 3. Van Itallie T. B., Am. J. Clin. Nutr. 1978, 31, S43. [DOI] [PubMed] [Google Scholar]
- 4. Oliveira M. C., Menezes‐Garcia Z., Henriques M. C. C., Soriani F. M., Pinho V., Faria A. M. C., Santiago A. F., Cara D. C., Souza D. G., Teixeira M. M., Ferreira A. V. M., Obesity 2013, 21, E396. [DOI] [PubMed] [Google Scholar]
- 5. Berer K., Martínez I., Walker A., Kunkel B., Schmitt‐Kopplin P., Walter J., Krishnamoorthy G., Sci. Rep. 2018, 11, 10431. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Burkitt D. P., Walker A. R. P., Painter N. S., Lancet 1972, 2, 1408. [DOI] [PubMed] [Google Scholar]
- 7. Beukema M., Faas M. M., de Vos P., Exp. Mol. Med. 2020, 52, 1364. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Smith P. M., Howitt M. R., Panikov N., Michaud M., Gallini C. A., Bohlooly‐Y M., Glickman J. N., Garrett W. S., Science (80‐.) 2013, 341, 569. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Oerlemans M. M. P., Akkerman R., Ferrari M., Walvoort M. T. C., de Vos P., J. Funct. Foods 2021, 76, 104289. [Google Scholar]
- 10. Desai M. S., Seekatz A. M., Koropatkin N. M., Kamada N., Hickey C. A., Wolter M., Pudlo N. A., Kitamoto S., Terrapon N., Muller A., Young V. B., Henrissat B., Wilmes P., Stappenbeck T. S., Núñez G., Martens E. C., Cell 2016, 167, 1339.e21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Beukema M., Ishisono K., de Waard J., Faas M. M., de Vos P., Kitaguchi K., Food Funct. 2021, 12, 881. [DOI] [PubMed] [Google Scholar]
- 12. Larsen N., Bussolo de Souza C., Krych L., Barbosa Cahú T., Wiese M., Kot W., Hansen K. M., Blennow A., Venema K., Jespersen L., Front. Microbiol. 2019, 10, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Ishisono K., Yabe T., Kitaguchi K., J. Nutr. Biochem. 2017, 50, 38. [DOI] [PubMed] [Google Scholar]
- 14. Sahasrabudhe N. M., Beukema M., Tian L., Troost B., Scholte J., Bruininx E., Bruggeman G., van den Berg M., Scheurink A., Schols H. A., Faas M. M., de Vos P., Front. Immunol. 2018, 9, 383. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Voragen A. G. J., Coenen G. J., Verhoef R. P., Schols H. A., Struct. Chem. 2009, 20, 263. [Google Scholar]
- 16. Thakur B. R., Singh R. K., Handa A. K., Rao M. A., Crit. Rev. Food Sci. Nutr. 1997, 37, 47. [DOI] [PubMed] [Google Scholar]
- 17. Daas P. J. H., Meyer‐Hansen K., Schols H. A., de Ruiter G. A., Voragen A. G. J., Carbohydr. Res. 1999, 318, 135. [Google Scholar]
- 18. Beukema M., Jermendi É., van den Berg M. A., Faas M. M., Schols H. A., de Vos P., Carbohydr. Polym. 2021, 251, 117093. [DOI] [PubMed] [Google Scholar]
- 19. Dongowski G., Lorenz A., Proll J., J. Nutr. 2002, 132, 1935. [DOI] [PubMed] [Google Scholar]
- 20. Tian L., Scholte J., Borewicz K., van den Bogert B., Smidt H., Scheurink A. J. W., Gruppen H., Schols H. A., Mol. Nutr. Food Res. 2016, 60, 2256. [DOI] [PubMed] [Google Scholar]
- 21. Tian L., Bruggeman G., van den Berg M., Borewicz K., Scheurink A. J. W., Bruininx E., de Vos P., Smidt H., Schols H. A., Gruppen H., Mol. Nutr. Food Res. 2017, 61, 1600186. [DOI] [PubMed] [Google Scholar]
- 22. Collins J. W., Keeney K. M., Crepin V. F., Rathinam V. A. K., a Fitzgerald K., Finlay B. B., Frankel G., Nat. Rev. Microbiol. 2014, 12, 612. [DOI] [PubMed] [Google Scholar]
- 23. Lupp C., Robertson M. L., Wickham M. E., Sekirov I., Champion O. L., Gaynor E. C., Finlay B. B., Cell Host Microbe 2007, 2, 119. [DOI] [PubMed] [Google Scholar]
- 24. Jiminez J. A., Uwiera T. C., Abbott D. W., Uwiera R. R. E., Inglis G. D., Gut Pathog 2016, 8, 67. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Rodrigues D. M., Sousa A. J., Johnson‐Henry K. C., Sherman P. M., Gareau M. G., J. Infect. Dis. 2012, 206, 99. [DOI] [PubMed] [Google Scholar]
- 26. Wu C., Pan L.‐L., Niu W., Fang X., Liang W., Li J., Li H., Pan X., Chen W., Zhang H., Lakey J. R. T., Agerberth B., de Vos P., Sun J., Front. Immunol. 2019, 10, 1733. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Ishisono K., Mano T., Yabe T., Kitaguchi K., Front. Immunol. 2019, 10, 2979. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Wine E., Shen‐Tu G., Gareau M. G., Goldberg H. A., Licht C., Ngan B.‐Y., Sorensen E. S., Greenaway J., Sodek J., Zohar R., Sherman P. M., Am. J. Pathol. 2010, 177, 1320. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Woting A., Blaut M., Nutrients 2018, 10, 685. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Faas M. M., Liu Y., Borghuis T., van Loo‐Bouwman C. A., Harmsen H., de Vos P., Front. Immunol. 2020, 10, 2976. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Sagaidak S., Taibi A., Wen B., Comelli E. M., J. Microbiol. Methods 2016, 126, 76. [DOI] [PubMed] [Google Scholar]
- 32. Ladirat S. E., Schols H. A., Nauta A., Schoterman M. H. C., Schuren F. H. J., Gruppen H., Bioact. Carbohydrates Diet. Fibre 2014, 3, 59. [Google Scholar]
- 33. Hammer Ø., Harper D. A. T., Ryan P. D., Palaeontol. Electron. 2001, 4, 9. [Google Scholar]
- 34. Makki K., Deehan E. C., Walter J., Bäckhed F., Cell Host Microbe 2018, 23, 705. [DOI] [PubMed] [Google Scholar]
- 35. Mundy R., MacDonald T. T., Dougan G., Frankel G., Wiles S., Cell. Microbiol. 2005, 7, 1697. [DOI] [PubMed] [Google Scholar]
- 36. Wohlfert E. A., Grainger J. R., Bouladoux N., Konkel J. E., Oldenhove G., Ribeiro C. H., Hall J. A., Yagi R., Naik S., Bhairavabhotla R., Paul W. E., Bosselut R., Wei G., Zhao K., Oukka M., Zhu J., Belkaid Y., J. Clin. Invest. 2011, 121, 4503. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Ohnmacht C., Park J. H., Cording S., Wing J. B., Atarashi K., Obata Y., Gaboriau‐Routhiau V., Marques R., Dulauroy S., Fedoseeva M., Busslinger M., Cerf‐Bensussan N., Boneca I. G., Voehringer D., Hase K., Honda K., Sakaguchi S., Eberl G., Science (80‐.) 2015, 349, 989. [DOI] [PubMed] [Google Scholar]
- 38. Jimenez A. G., Ellermann M., Abbott W., Sperandio V., Nat. Microbiol. 2020, 5, 368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Kamada N., Kim Y. G., Sham H. P., Vallance B. A., Puente J. L., Martens E. C., Núñez G., Science (80‐.) 2012, 336, 1325. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Osbelt L., Thiemann S., Smit N., Lesker T. R., Schröter M., Gálvez E. J. C., Schmidt‐Hohagen K., Pils M. C., Mühlen S., Dersch P., Hiller K., Schlüter D., Neumann‐Schaal M., Strowig T., PLoS Pathog. 2020, 16, e1008448. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Stackebrandt E., in The Prokaryotes (Eds.: Rosenberg E., DeLong E. f., Lory S., Stackebrandt E., Thompson F.), 2014, pp. 197. [Google Scholar]
- 42. Jiminez J. A., Uwiera T. C., Abbott D. W., Uwiera R. R. E., Inglis G. D., mSphere 2017, 2, e00243. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Cummings J. H., Gut 1981, 22, 763. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Wang Z., Friedrich C., Hagemann S. C., Korte W. H., Goharani N., Cording S., Eberl G., Sparwasser T., Lochner M., Mucosal Immunol. 2014, 7, 1290. [DOI] [PubMed] [Google Scholar]
- 45. Cosovanu C., Neumann C., Front. Immunol. 2020, 11, 600973. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Higgins L. M., Frankel G., Douce G., Dougan G., MacDonald T. T., Infect. Immun. 1999, 67, 3031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Gibson D. L., Ma C., Bergstrom K. S. B., Huang J. T., Man C., Vallance B. A., Cell. Microbiol. 2008, 10, 618. [DOI] [PubMed] [Google Scholar]
- 48. Bergstrom K. S. B., Kissoon‐Singh V., Gibson D. L., Ma C., Montero M., Sham H. P., Ryz N., Huang T., Velcich A., Finlay B. B., Chadee K., Vallance B. A., PLoS Pathog. 2010, 6, e1000902. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Research data are not shared.